ZA200300894B - Prodrugs to NMDA receptor ligands. - Google Patents

Prodrugs to NMDA receptor ligands. Download PDF

Info

Publication number
ZA200300894B
ZA200300894B ZA200300894A ZA200300894A ZA200300894B ZA 200300894 B ZA200300894 B ZA 200300894B ZA 200300894 A ZA200300894 A ZA 200300894A ZA 200300894 A ZA200300894 A ZA 200300894A ZA 200300894 B ZA200300894 B ZA 200300894B
Authority
ZA
South Africa
Prior art keywords
compound
formula
piperidin
hydroxy
ethanesulfonyl
Prior art date
Application number
ZA200300894A
Other languages
English (en)
Inventor
Alexander Alanine
Holger Fisher
Joerg Huwyler
Emmmanuel Pinard
Bernd Beuttelmann
Heitz Neidhart Marie-Paule
Georg Jaeschke
Rene Wyler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200300894B publication Critical patent/ZA200300894B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA200300894A 2000-08-21 2003-01-31 Prodrugs to NMDA receptor ligands. ZA200300894B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00117918 2000-08-21

Publications (1)

Publication Number Publication Date
ZA200300894B true ZA200300894B (en) 2004-04-30

Family

ID=8169594

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200300894A ZA200300894B (en) 2000-08-21 2003-01-31 Prodrugs to NMDA receptor ligands.

Country Status (35)

Country Link
US (1) US6407235B1 (cg-RX-API-DMAC7.html)
EP (1) EP1313703B1 (cg-RX-API-DMAC7.html)
JP (1) JP4162991B2 (cg-RX-API-DMAC7.html)
KR (1) KR100589991B1 (cg-RX-API-DMAC7.html)
CN (1) CN1227230C (cg-RX-API-DMAC7.html)
AR (1) AR030373A1 (cg-RX-API-DMAC7.html)
AT (1) ATE386022T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001285894B2 (cg-RX-API-DMAC7.html)
BR (1) BR0113348A (cg-RX-API-DMAC7.html)
CA (1) CA2419279C (cg-RX-API-DMAC7.html)
CY (1) CY1107937T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ303319B6 (cg-RX-API-DMAC7.html)
DE (1) DE60132782T2 (cg-RX-API-DMAC7.html)
DK (1) DK1313703T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP034489A (cg-RX-API-DMAC7.html)
EG (1) EG24293A (cg-RX-API-DMAC7.html)
ES (1) ES2299508T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20030125B1 (cg-RX-API-DMAC7.html)
HU (1) HU229802B1 (cg-RX-API-DMAC7.html)
IL (1) IL154254A0 (cg-RX-API-DMAC7.html)
JO (1) JO2289B1 (cg-RX-API-DMAC7.html)
MA (1) MA26947A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA03001311A (cg-RX-API-DMAC7.html)
MY (1) MY136065A (cg-RX-API-DMAC7.html)
NO (1) NO324941B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ523990A (cg-RX-API-DMAC7.html)
PA (1) PA8525601A1 (cg-RX-API-DMAC7.html)
PE (1) PE20020291A1 (cg-RX-API-DMAC7.html)
PL (1) PL204215B1 (cg-RX-API-DMAC7.html)
PT (1) PT1313703E (cg-RX-API-DMAC7.html)
RS (1) RS51467B (cg-RX-API-DMAC7.html)
RU (1) RU2272027C2 (cg-RX-API-DMAC7.html)
SI (1) SI1313703T1 (cg-RX-API-DMAC7.html)
WO (1) WO2002016321A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200300894B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2245876C2 (ru) * 2000-03-21 2005-02-10 Дзе Проктер Энд Гэмбл Компани Производные сульфонамидов и фармацевтическая композиция на их основе
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
CN101374801B (zh) * 2005-12-19 2014-07-02 梅特希尔基因公司 用于增强抗真菌剂活性的组蛋白脱乙酰酶抑制剂
JP2010513326A (ja) 2006-12-19 2010-04-30 メシルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害薬及びそのプロドラッグ
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
KR102336426B1 (ko) 2013-11-05 2021-12-08 아스트라제네카 아베 Nmda 길항제 전구약물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9408506A (pt) * 1994-01-31 1997-08-05 Pfizer Compostos neuroprotetores
DE4410822A1 (de) 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
TWI254043B (en) 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor

Also Published As

Publication number Publication date
CA2419279C (en) 2008-10-14
HUP0301548A3 (en) 2010-03-29
EP1313703A1 (en) 2003-05-28
JO2289B1 (en) 2005-09-12
NO324941B1 (no) 2008-01-07
KR20030022417A (ko) 2003-03-15
CA2419279A1 (en) 2002-02-28
SI1313703T1 (sl) 2008-06-30
RU2272027C2 (ru) 2006-03-20
DE60132782T2 (de) 2009-02-05
PE20020291A1 (es) 2002-04-17
KR100589991B1 (ko) 2006-06-15
EP1313703B1 (en) 2008-02-13
CZ303319B6 (cs) 2012-08-01
YU13003A (sh) 2006-05-25
JP4162991B2 (ja) 2008-10-08
NZ523990A (en) 2004-09-24
PL361387A1 (en) 2004-10-04
CN1447793A (zh) 2003-10-08
AU2001285894B2 (en) 2006-06-15
HRP20030125A2 (en) 2005-02-28
BR0113348A (pt) 2003-07-08
US6407235B1 (en) 2002-06-18
JP2004506715A (ja) 2004-03-04
CN1227230C (zh) 2005-11-16
PT1313703E (pt) 2008-03-25
AR030373A1 (es) 2003-08-20
MA26947A1 (fr) 2004-12-20
AU8589401A (en) 2002-03-04
HK1059083A1 (en) 2004-06-18
DK1313703T3 (da) 2008-05-19
PL204215B1 (pl) 2009-12-31
EG24293A (en) 2009-01-08
RS51467B (sr) 2011-04-30
NO20030781D0 (no) 2003-02-19
CZ2003492A3 (cs) 2004-01-14
ES2299508T3 (es) 2008-06-01
MXPA03001311A (es) 2003-06-30
WO2002016321A1 (en) 2002-02-28
PA8525601A1 (es) 2002-04-25
HUP0301548A2 (hu) 2003-08-28
NO20030781L (no) 2003-02-19
DE60132782D1 (de) 2008-03-27
CY1107937T1 (el) 2013-09-04
US20020040037A1 (en) 2002-04-04
ATE386022T1 (de) 2008-03-15
MY136065A (en) 2008-08-29
HU229802B1 (hu) 2014-07-28
IL154254A0 (en) 2003-09-17
HRP20030125B1 (en) 2011-07-31
ECSP034489A (es) 2003-03-31

Similar Documents

Publication Publication Date Title
EP0383579B1 (en) N-Phenyl-N-(4-piperidinyl)amides useful as analgesics
JP3302351B2 (ja) 神経栄養活性および神経保護活性を有する4−アリール−1−フェニルアルキル−1,2,3,6−テトラヒドロピリジン
PL171693B1 (pl) Sposób wytwarzania nowych pochodnych benzotiazoloalkanonopiperydyny PL PL PL PL PL
PT96405B (pt) Processo para a preparacao de derivados da 3-aminopiperidina e de heterociclos afins contendo azoto
EP0374801A2 (en) Novel N-sustituted azaheterocyclic carboxylic acids
US5053521A (en) Various n-substituted 3-piperidine carboxylic acids or n-substituted 3-pyridinecarboxylic acids and derivatives thereof
EP0587194B1 (en) 2-(Heterocycloalkoxy)-1-(subst.-phenyl)-ethanol derivatives as cerebral function improving agents
EP0816338B1 (en) 3-(bis-substituted-phenylmethylene)oxindole derivatives
EP1313703B1 (en) Prodrugs to nmda receptor ligands
AU2001285894A1 (en) Prodrugs to NMDA receptor ligands
US5071858A (en) Antipsychotic benzothiopyranylamines
EP3945092A1 (en) Carbaldehyde oximes as butyrylcholinesterase reactivators
US5214148A (en) Analgesic N-phenyl-N-(3-OR1 -3-ME-4-piperidinyl)amides
WO1995025100A1 (fr) Utilisation d'esters de l'acide 4-amino-5-chloro-2-methoxybenzoique comme 5-ht4 agonistes
FI113869B (fi) Menetelmä 5,7-dihydro-3-[2-(1-bentsyylipiperidin-4-yyli)etyyli]-6H-pyrrolo[4,5-f]-1,2-bentsioksatsol-6-onin valmistamiseksi
JP2000319258A (ja) 4−置換ピペリジン誘導体フッ化物
EP0508004A1 (en) Phenylsulfonylalkanoic acid compounds
JPH02212472A (ja) ジフエニルメトキシエチルピペリジン誘導体
MXPA99007937A (en) Quinoxalinediones